Fundació Lluita contra les Infeccions and the clinical fight to make HIV care faster, smarter and more durable
- Editorial Team SDG3
- 2 days ago
- 6 min read
Published on 3 June 2026 at 03:05 GMT
By Editorial Team SDG3
Fundació Lluita contra les Infeccions occupies a specific place in the global HIV response: it is not a campaigning body or a pharmaceutical company, but a non-profit clinical research and care organisation working at the point where patients, hospitals and experimental science meet. Based in Catalonia, its work on HIV treatment, therapeutic vaccines and early diagnosis pathways reflects one of the central questions in infectious disease policy today, how health systems can move beyond keeping people alive towards reducing long-term burden, improving quality of care and preparing for future infections.
Founded in 1992 at Germans Trias i Pujol University Hospital by Dr Bonaventura Clotet, the foundation emerged from the urgency of the AIDS crisis and the need to support specialist HIV care, research and training. Its public identity has since broadened from HIV to infectious diseases more widely, including sexually transmitted infections, severe bacterial infections, emerging respiratory infections, international health and infections affecting immunocompromised people. Yet HIV remains one of the clearest examples of its operating model: clinical problems seen in care settings are turned into research questions, and research findings are tested against the realities of diagnosis, treatment and follow-up.
That model matters because HIV is no longer the same public health emergency it was in the 1980s and 1990s, but it is not over. Antiretroviral therapy has transformed HIV from a frequently fatal infection into a manageable chronic condition for many people with access to treatment. It also prevents onward transmission when viral load is durably suppressed. The unresolved problem is that daily or long-acting treatment is still required, health inequalities shape who is diagnosed early, and stigma continues to influence testing, disclosure and care. In that context, clinical HIV research is not an abstract scientific project. It affects whether people start treatment quickly, remain in care, avoid complications and benefit from new therapeutic approaches.
The foundation’s work on early HIV diagnosis is especially relevant to public health. Early diagnosis allows treatment to begin before the immune system is seriously damaged and reduces the period in which the virus may be passed on unknowingly. The organisation has highlighted rapid treatment initiation after diagnosis as one of its care priorities, including programmes designed to shorten the time between a positive test and antiretroviral therapy. Such pathways are practical rather than symbolic. They depend on trained clinicians, laboratory capacity, referral systems, counselling, community trust and the ability of hospitals to respond quickly when someone receives life-changing news.
This is where the foundation’s role differs from that of many research institutions. Its proximity to hospital care gives it access to the clinical realities that determine whether innovations work outside controlled trial settings. A faster pathway is not useful if patients are lost between testing and appointment. A new therapy is limited if it is too complex, expensive or unsuitable for people with other health conditions. Patient-centred infectious disease care requires more than biomedical progress, it requires systems that can translate evidence into ordinary clinical practice.
The foundation is also associated with one of the most contested and important frontiers in HIV science: the search for a functional cure or durable control without continuous treatment. Its public materials describe clinical trials involving therapeutic HIV vaccines, including approaches intended to strengthen immune responses in people already living with HIV. This field should be reported carefully. A therapeutic vaccine is not the same as a preventive vaccine, and it is not proof of a cure. The scientific aim is to help the immune system control the virus more effectively, potentially reducing dependence on lifelong treatment for some people if future evidence supports that outcome.
The challenge is formidable. HIV integrates into the body’s cells and can persist in viral reservoirs that remain difficult to reach. When treatment stops, the virus commonly rebounds. Research into reservoirs, immune responses and vaccine strategies therefore sits at the edge of what current medicine can do. Fundació Lluita contra les Infeccions has worked in this space alongside a wider scientific ecosystem in Barcelona and beyond, including IrsiCaixa, a major HIV and immunology research institute, and specialist networks involved in vaccine and cure-related research. The public-interest importance lies not in promising a breakthrough, but in sustaining careful, ethically governed research where progress is incremental and uncertainty is unavoidable.
That caution is essential. HIV cure research has sometimes been framed in public debate with more hope than evidence. For people living with HIV, exaggerated claims can be harmful, particularly when treatment adherence remains critical. Responsible organisations must balance scientific ambition with clear communication about trial phases, eligibility, risks and limits. The foundation’s clinical orientation gives it a responsibility to keep that balance visible, especially when research involves people who may have lived through decades of medical stigma and changing treatment expectations.
The organisation’s broader infectious disease work also reflects lessons from HIV. The COVID-19 pandemic showed that health systems need research capacity embedded close to clinical care, not assembled only after emergencies begin. Fundació Lluita contra les Infeccions expanded its work into SARS-CoV-2 and persistent COVID-19, while maintaining research lines on bacterial infections, sexually transmitted infections and neglected diseases. This breadth can be a strength because immune science, diagnostics, trial design and patient follow-up often overlap across infections. It can also create pressure, as non-profit clinical research organisations must decide how to allocate staff, funding and attention across urgent and chronic health threats.
Funding is one of the less visible but decisive issues. Non-profit biomedical research depends on a mix of public grants, philanthropy, institutional partnerships and, in some cases, collaboration with private companies. Such relationships can accelerate trials and support innovation, but they also require transparency, strong governance and independence in scientific decision-making. For a foundation working on vaccines and treatment strategies, public trust depends not only on results but on how studies are designed, reviewed and communicated.
The Barcelona setting is significant. Catalonia has developed a dense HIV and infectious disease research environment, with hospitals, public health bodies and research institutes working across epidemiology, virology, immunology and clinical care. Germans Trias i Pujol University Hospital, IrsiCaixa and public health agencies provide part of the infrastructure in which the foundation operates. This concentration can help move discoveries from laboratory to clinic more efficiently. It also places local institutions within a global problem, since HIV prevention, diagnosis and treatment remain unevenly distributed between and within countries.
The foundation’s work connects most directly to SDG 3 (good health and well-being), particularly the goal of ending AIDS as a public health threat and improving access to quality health services. Its relevance also touches SDG 10 (reduced inequalities) where early diagnosis and care pathways address gaps affecting people who face stigma, poverty, migration barriers or limited access to specialist services. These links are not decorative. HIV outcomes are shaped by inequality as much as by medicine, and any serious research agenda must account for who benefits from scientific progress.
Civil society has long been central to the HIV response, from treatment activism to peer support, prevention education and rights-based advocacy. Organisations such as NAM aidsmap, International AIDS Society, European AIDS Treatment Group and AVAC occupy different roles from the foundation, but they form part of the wider ecosystem that scrutinises evidence, supports community understanding and presses for equitable access. Their relevance underlines a key point: HIV science advances most effectively when clinical research, public health and affected communities remain in conversation.
The practical significance of Fundació Lluita contra les Infeccions is therefore not only that it conducts research, but that it works in a field where research can quickly alter care pathways. Earlier diagnosis can change a patient’s long-term prognosis. Better treatment strategies can reduce side effects and complexity. Vaccine and reservoir studies can test whether HIV control may one day become less dependent on lifelong therapy. None of these outcomes is guaranteed, and all require sustained evidence, funding and ethical oversight.
For global health readers, the foundation illustrates a wider shift in infectious disease work. The most effective institutions are no longer only laboratories, hospitals or advocacy groups in isolation. They are organisations able to connect evidence, care delivery and public accountability. Fundació Lluita contra les Infeccions sits within that demanding space. Its contribution will be judged not by scientific promise alone, but by whether its research helps people receive faster diagnosis, safer treatment and more realistic options for living with, and perhaps one day controlling, HIV in new ways.
Further information:
Fundació Lluita contra les Infeccions, the main organisation profiled here, is a non-profit clinical research and care foundation focused on infectious diseases, including HIV treatment, vaccines and diagnosis pathways.
Germans Trias i Pujol University Hospital, the hospital setting in which the foundation was established, is central to its clinical research environment.
IrsiCaixa, a Barcelona-based HIV and immunology research institute, is relevant for its work on viral reservoirs, cure research and infectious disease science.
International AIDS Society, a global professional association, is relevant for its role in convening HIV science, policy and clinical expertise.
NAM aidsmap, a non-profit HIV information organisation, is relevant for its evidence-based public information on HIV treatment, prevention and care.
